🔆 Beacon

← Search all trials on Beacon

Daridorexant for Alzheimer Disease Prevention

Recruiting now Phase 2 NCT07213349

Run by Douglas Mental Health University Institute · for 50 to 90 · All sexes · accepts healthy volunteers

What this study is about

This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer's disease dementia, regardless of whether or not they experience sleep problems.

Who can join (things the study team will check)

✅ You may be able to join if…

🚫 You may not be able to join if…

Where this trial is running

Who to contact

Jennifer Tremblay-Mercier, MSc · 855-888-4485 · prevenir.alzheimer@douglas.mcgill.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07213349.

Open the interactive checklist for this trial →

Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.

Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.